Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dystrophia Myotonica 2 Clear all
Withdrawn Not applicable Interventional

CGM/Clarity Use, Glycemic Control and Clinical Outcomes

NCT03827434
View directory record Official record
Conditions
Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions
Continuous glucose Monitoring Devices and Clarity Software, Point of Care (POC) blood glucose
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 17, 2026, 11:45 PM EDT
Recruiting No phase listed Observational

Myotonic Dystrophy Family Registry

NCT02398786
View directory record Official record
Conditions
Myotonic Dystrophy, Congenital Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Dystrophy 2, Dystrophia Myotonica, Dystrophia Myotonica 1, Dystrophia Myotonica 2, Myotonia Dystrophica, Myotonic Dystrophy, Congenital, Myotonic Myopathy, Proximal, PROMM (Proximal Myotonic Myopathy), Proximal Myotonic Myopathy, Steinert Disease, Steinert Myotonic Dystrophy, Steinert's Disease, Myotonia Atrophica
Interventions
Patient-entered data
Other
Lead sponsor
Myotonic Dystrophy Foundation
Other
Eligibility
Not listed
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

NCT01976169
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
PD-0332991 and T-DM1
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 17, 2026, 11:45 PM EDT
Terminated Phase 1Phase 2 Interventional

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

NCT03709082
View directory record Official record
Conditions
HER2-positive Breast Cancer, Breast Cancer Metastatic
Interventions
Palbociclib 75mg, Letrozole 2.5mg, T-DM1, Palbociclib 100mg, Palbociclib 125mg, Palbociclib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 17, 2026, 11:45 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

NCT06828588
View directory record Official record
Conditions
Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Interventions
[68Ga]Ga-ABY-025
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT05479981
View directory record Official record
Conditions
DM1, Muscular Dystrophies, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Disorders, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, Neurodegenerative Diseases
Interventions
Placebo, AOC 1001
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Phase 1Phase 2 Interventional

MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

NCT00070837
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
MLN2704 (DM1 conjugated monoclonal antibody MLN591)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2007 · Synced Sep 17, 2026, 11:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

NCT03587740
View directory record Official record
Conditions
Breast Cancer
Interventions
T-DM1
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
60 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
14
States / cities
Duarte, California • Stamford, Connecticut • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 17, 2026, 11:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

NCT03529110
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
28
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 17, 2026, 11:45 PM EDT
Recruiting Not applicable Interventional

Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)

NCT06716931
View directory record Official record
Conditions
Myotonic Dystrophy 2
Interventions
Exercise
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Not applicable Interventional Results available

Improving Glycemic Control in DM2 Patients in the Ambulatory Setting

NCT04800471
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Smart insulin pens and CGM, Point of Care Glucose Group
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT00509769
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab emtansine [Kadcyla]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Phase 4 Interventional Results available

Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

NCT03782259
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
Interventions
dapagliflozin, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 17, 2026, 11:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

NCT00082108
View directory record Official record
Conditions
Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, Muscular Dystrophy, Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 2, Congenital Myotonic Dystrophy, PROMM (Proximal Myotonic Myopathy), Steinert's Disease, Myotonic Muscular Dystrophy
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

NCT01196052
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Fort Myers, Florida • Lafayette, Indiana • Scarborough, Maine + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2014 · Synced Sep 17, 2026, 11:45 PM EDT
Recruiting Not applicable Interventional

Improving Glycemic Control With Telemedicine and Smart Insulin Pens

NCT06918977
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
InPen Smart insulin pen, traditional/standard insulin pen
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea

NCT01447251
View directory record Official record
Conditions
Obstructive Sleep Apnea, Diabetes Mellitus
Interventions
PreDx Diabetes Risk Score
Behavioral
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Sep 17, 2026, 11:45 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

NCT05874635
View directory record Official record
Conditions
Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity, Insulin Resistance, Glucose Intolerance, Metabolic Glucose Disorders
Interventions
Continuous Glucose Monitor Device
Device
Lead sponsor
Signos Inc
Industry
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

NCT02073916
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
T-DM1, Lapatinib, Abraxane
Drug
Lead sponsor
Jenny C. Chang, MD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 17, 2026, 11:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

NCT03248492
View directory record Official record
Conditions
Breast Cancer
Interventions
DS-8201a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
36
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Phase 1Phase 2 Interventional

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT05027269
View directory record Official record
Conditions
DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions
AOC 1001, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 17, 2026, 11:45 PM EDT
Terminated No phase listed Observational

Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)

NCT03867435
View directory record Official record
Conditions
Myotonic Dystrophy Type-1, Myotonic Dystrophy Type-2
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
11 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 17, 2026, 11:45 PM EDT
Completed Not applicable Interventional

A Study to Assess the Effect of Psyllium vs. Wheat Dextrin on Glycemic Control and Inflammatory Markets in Diabetes Mellitus 2

NCT04547790
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Psyllium, Wheat Dextrin
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 17, 2026, 11:45 PM EDT